Back

Elamipretide in heart failure with reduced ejection fraction.

22 May 2016 (13:15 - 13:30)
Organised by:
Congress Presentation Part of: Targeting mitochondria to improve outcomes in heart failure Cell Signalling HFA Premium Access HEART FAILURE 2016

About the speaker

Photo
Professor Hani Sabbah

Henry Ford Hospital, Detroit (United States of America)

3 More presentations in this session

Presentation thumbnail
Reaching the next level of drug development for heart failure: targetting mitochondria.
Professor S. Anker (Berlin, DE)
Presentation thumbnail
Elamipretide improves mitochondrial activity in the failing human heart.
Doctor B. Stauffer (Aurora, US)
Presentation thumbnail
Clinical development concepts targeting mitochondria.
Professor B. Pitt (Ann Arbor, US)

Access the full session

Session thumbnail
Targeting mitochondria to improve outcomes in heart failure

The Event

Event poster

HEART FAILURE 2016

22 May 2016 13:15 CET
You may be interested in
thumbnail
Congress Presentation
Improving management of heart failure with reduced ejection fraction with sglt2i's using the latest clinical data: an online education intervention
27 August 2021
thumbnail
Congress Presentation
Mitochondrial targeting by Elamipretide improves cardiac mitochondrial function without improving cardiovascular performance in HFpEF
23 April 2026
thumbnail
Congress Session
Evolving treatment paradigms in heart failure: from SGLT2 inhibition to transthyretin stabilisation and beyond
20 May 2025
thumbnail
Congress Presentation
Patients with transthyretin amyloid cardiomyopathy may have preserved, mildly reduced, or reduced ejection fraction
27 August 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources